Prognosis in heart failure and the value of β-blockers are altered by the use of antidepressants and depend on the type of antidepressants used

Circulation: Heart Failure

Volumn 2, Issue 6, 2009, Pages 582-590

  Fosbøl, Emil Loldrup ^a   Gislason, Gunnar H ^b   Poulsen, Henrik Enghusen ^c,d   Hansen, Morten Lock ^a   Folke, Fredrik ^a   Schramm, Tina Ken ^a   Olesen, Jonas Bjerring ^a   Bretler, Ditte Marie ^a   Abildstrøm, Steen Z ^e,f   Sørensen, Rikke ^a   Hvelplund, Anders ^a,f   Køber, Lars ^b,d   Torp Pedersen, Christian ^a,d  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c Rigshospitalet   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

blockers; Antidepressants; Cardiovascular mortality; Depression; Heart failure; Mortality; Pharmacology

Indexed keywords

ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FUROSEMIDE; SEROTONIN UPTAKE INHIBITOR; SPIRONOLACTONE; STATIN; TRICYCLIC ANTIDEPRESSANT AGENT;

AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HAZARD RATIO; HEART DEATH; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SURVIVAL;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COHORT STUDIES; DENMARK; DEPRESSION; DRUG INTERACTIONS; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952041797     PISSN: 19413289     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.109.851246     Document Type: Article

References (44)

1. Carney RM, Rich MW, Freedland KE, Saini J, teVelde A, Simeone C, Clark K. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med. 1988;50:627-633.
2. Connerney I, Shapiro PA, McLaughlin JS, Bagiella E, Sloan RP. Relation between depression after coronary artery bypass surgery and 12-month outcome: a prospective study. Lancet. 2001;358:1766-1771.
3. Denollet J, Sys SU, Stroobant N, Rombouts H, Gillebert TC, Brutsaert DL. Personality as independent predictor of long-term mortality in patients with coronary heart disease. Lancet. 1996;347:417-421.
4. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction. Impact on 6-month survival. JAMA. 1993;270: 1819-1825.
5. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation. 1995;91:999-1005.
6. Ladwig KH, Roll G, Breithardt G, Budde T, Borggrefe M. Post-infarction depression and incomplete recovery 6 months after acute myocardial infarction. Lancet. 1994;343:20-23.
7. Selman L, Beynon T, Higginson IJ, Harding R. Psychological, social and spiritual distress at the end of life in heart failure patients. Curr Opin Support Palliat Care. 2007;1:260-266.
8. Abramson J, Berger A, Krumholz HM, Vaccarino V. Depression and risk of heart failure among older persons with isolated systolic hypertension. Arch Intern Med. 2001;161:1725-1730.
9. Jiang W, Alexander J, Christopher E, Kuchibhatla M, Gaulden LH, Cuffe MS, Blazing MA, Davenport C, Califf RM, Krishnan RR, O'Connor CM. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med. 2001; 161:1849-1856.
10. Jiang W, Kuchibhatla M, Clary GL, Cuffe MS, Christopher EJ, Alexander JD, Califf RM, Krishnan RR, O'Connor CM. Relationship between depressive symptoms and long-term mortality in patients with heart failure. Am Heart J. 2007;154:102-108.
11. Vaccarino V, Kasl SV, Abramson J, Krumholz HM. Depressive symptoms and risk of functional decline and death in patients with heart failure. J Am Coll Cardiol. 2001;38:199-205.
12. Gehi A, Haas D, Pipkin S, Whooley MA. Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. Arch Intern Med. 2005;165:2508-2513.
13. Ziegelstein RC, Fauerbach JA, Stevens SS, Romanelli J, Richter DP, Bush DE. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. Arch Intern Med. 2000;160:1818-1823.
14. Ruo B, Rumsfeld JS, Pipkin S, Whooley MA. Relation between depressive symptoms and treadmill exercise capacity in the Heart and Soul Study. Am J Cardiol. 2004;94:96-99.
15. Whooley MA, de Jonge P, Vittinghoff E, Otte C, Moos R, Carney RM, Ali S, Dowray S, Na B, Feldman MD, Schiller NB, Browner WS. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA. 2008;300:2379-2388.
16. Otte C, Neylan TC, Pipkin SS, Browner WS, Whooley MA. Depressive symptoms and 24-hour urinary norepinephrine excretion levels in patients with coronary disease: findings from the Heart and Soul Study. Am J Psychiatry. 2005;162:2139-2145.
17. Schins A, Hamulyak K, Scharpe S, Lousberg R, Van Melle J, Crijns H, Honig A. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sci. 2004;76:637-650.
18. Konig F, Hafele M, Hauger B, Loble M, Wossner S, Wolfersdorf M. [Bradycardia after beginning therapy with metoprolol and paroxetine]. Psychiatr Prax. 1996;23:244-245 [in German].
19. Sherwood A, Blumenthal JA, Trivedi R, Johnson KS, O'Connor CM, Adams KF Jr, Dupree CS, Waugh RA, Bensimhon DR, Gaulden L, Christenson RH, Koch GG, Hinderliter AL. Relationship of depression to death or hospitalization in patients with heart failure. Arch Intern Med. 2007;167:367-373.
20. Walley T, Pirmohamed M, Proudlove C, Maxwell D. Interaction of metoprolol and fluoxetine. Lancet. 1993;341:967-968.
21. Antidepressant medication treatment for depression in individuals with chronic heart failure. Available at: http://clinicaltrials.gov/ct2/show/ NCT00078286. Accessed March 17, 2009.
22. Escitalopram in depressive patients with acute coronary artery syndrome. Available at: http://clinicaltrials.gov/ct2/show/NCT00419471. Accessed March 23, 2009.
23. Jiang W, O'Connor C, Silva SG, Kuchibhatla M, Cuffe MS, Callwood DD, Zakhary B, Henke E, Arias RM, Krishnan R. Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF) : a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure. Am Heart J. 2008;156:437-444.
24. Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, Czajkowski SM, DeBusk R, Hosking J, Jaffe A, Kaufmann PG, Mitchell P, Norman J, Powell LH, Raczynski JM, Schneiderman N. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA. 2003;289: 3106-3116.
25. Davidson KW, Kupfer DJ, Bigger JT, Califf RM, Carney RM, Coyne JC, Czajkowski SM, Frank E, Frasure-Smith N, Freedland KE, Froelicher ES, Glassman AH, Katon WJ, Kaufmann PG, Kessler RC, Kraemer HC, Krishnan KR, Lesperance F, Rieckmann N, Sheps DS, Suls JM. Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report. Psychosom Med. 2006;68:645-650.
26. Gartside SE, Clifford EM, Cowen PJ, Sharp T. Effects of (-)-tertatolol, (-)-penbutolol and (+/-)-pindolol in combination with paroxetine on presynaptic 5-HT function: an in vivo microdialysis and electrophysiological study. Br J Pharmacol. 1999;127:145-152.
27. Mason GA, Walker CH, Little KY. Effects of concurrent subchronic treatments with desmethylimipramine and propranolol on beta-adrenergic and serotonin2 receptors in rat brain. Psychopharmacology (Berl). 1993; 110:110-114.
28. Jiang W, Davidson JR. Antidepressant therapy in patients with ischemic heart disease. Am Heart J. 2005;150:871-881.
29. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull. 1997;44:445-448.
30. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999;46:263-268.
31. Kumler T, Gislason GH, Kirk V, Bay M, Nielsen OW, Kober L, Torp-Pedersen C. Accuracy of a heart failure diagnosis in administrative registers. Eur J Heart Fail. 2008;10:658-660.
32. Fosbol EL, Gislason GH, Jacobsen S, Abildstrom SZ, Hansen ML, Schramm TK, Folke F, Sorensen R, Rasmussen JN, Kober L, Madsen M, Torp-Pedersen C. The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidemiol Drug Saf. 2008;17:822-833.
33. Gislason GH, Rasmussen JN, Abildstrom SZ, Gadsboll N, Buch P, Friberg J, Rasmussen S, Kober L, Stender S, Madsen M, Torp-Pedersen C. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006;27:1153-1158.
34. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Buch P, Sorensen R, Folke F, Gadsboll N, Rasmussen S, Kober L, Madsen M, Torp-Pedersen C. Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. Circulation. 2007;116:737-744.
35. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med. 2000;108:2-8.
36. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med. 1989;321:406-412.
37. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med. 1992;327:227-233.
38. Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT Jr, Pollock BG, Gaffney A, Narayan M, Finkel MS, McCafferty J, Gergel I. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA. 1998;279:287-291.
39. Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, Kaufmann PG, Shuster J, Mellman T, Blumenthal JA, Krishnan R, Jaffe AS. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2005;62:792-798.
40. Tousoulis D, Antoniades C, Drolias A, Stefanadi E, Marinou K, Vasiliadou C, Tsioufis C, Toutouzas K, Latsios G, Stefanadis C. Selective serotonin reuptake inhibitors modify the effect of beta-blockers on long-term survival of patients with end-stage heart failure and major depression. J Card Fail. 2008;14:456-464.
41. Mekontso-Dessap A, Brouri F, Pascal O, Lechat P, Hanoun N, Lanfumey L, Seif I, Benhaiem-Sigaux N, Kirsch M, Hamon M, Adnot S, Eddahibi S. Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation. 2006;113:81-89.
42. Otton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther. 1988;247:242-247.
43. Johnson JA, Burlew BS. Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. Drug Metab Dispos. 1996;24:350-355.
44. Belpaire FM, Wijnant P, Temmerman A, Rasmussen BB, Brosen K. The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors. Eur J Clin Pharmacol. 1998;54:261-264.